



Neut rop hi lic gra nu lo cytes expre ss their Fcγ re cep tor, al so known as the CD64 an ti gen, pre do mi nan tly when they are ac ti va ted. This ma kes neut rop-
hil CD64 a po ten tial bio mar ker for in fec tion and sep sis. In deed the re is am ple li te ra tu re on the diag nos tic uti lity of neut rop hil CD64 in a va rie ty of 
di sea ses. This re view sum ma ri zes the li te ra tu re on its ap pli ca tion as a sep sis bio mar ker, in adul ts as we ll as in neo na tes and in fan ts. The avai lab le da-
ta in di ca te that neut rop hil CD64 see ms to ha ve hi gh sen si ti vi ty (86%) and spe ci fi  ci ty (87%), but the met ho do lo gi cal qua li ty of mo st stu dies is ques-
tio nab le. Ne ver the le ss, neut rop hil CD64 ap pea rs to be a bet ter diag nos tic te st than tra di tio nal he ma to lo gi cal as says, C-reac ti ve pro tein and pro bab ly 
even pro cal ci to nin. Ap pli ca tion of neut rop hil CD64 in ot her con di tio ns than sep sis is briefl y pre sen ted. Fi nal ly, fu tu re cli ni cal stu dies are dis cus sed 
whi ch are nee ded in or der to con fi  rm the diag nos tic per for man ce of this pro mi si ng bio mar ker.
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Infl ammation
In tro duc tion
The hu man im mu ne res pon se is a hig hly com plex 
and de li ca te ba lan ce be tween pro- and an ti-in-
fl am ma to ry mec ha nis ms and in vol ves cel ls as we ll 
as cyto ki nes. When the im mu ne system is ac ti va-
ted, for exam ple by bac te rial in fec tion, the im mu-
ne res pon se is nor mal ly stric tly re gu la ted and the 
pro- and an ti-in fl am ma to ry pha ses are ba lan ced 
and synchro ni zed. In syste mic in fl am ma to ry res-
pon se syndro me (SIRS) the im mu ne system is ove-
r-sti mu la ted and the pro-in fl am ma to ry res pon se 
pre ce des the an ti-in fl am ma to ry reac tion: the nor-
mal ba lan ce is dis tur bed and out of pha se. The 
exce ss of pro-in fl am ma to ry cyto ki nes cau ses 
exces si ve ac ti va tion of leu ko cytes, re lea se of lytic 
en zymes and toxic ra di ca ls and en dot he lial da ma-
ge, whi ch re sul ts in in crea sed vas cu lar per mea bi li-
ty, cir cu la to ry dis tur ban ces and even tual ly or gan 
fai lu re. The exces si ve an ti-in fl am ma to ry pha se 
cau ses im mu ne sup pres sion, whi ch ma kes the pa-
tie nt mo re pro ne to se con da ry in fec tio ns (1).
SIRS is not ne ces sa ri ly cau sed by in fec tion as ot her 
even ts li ke ma jor sur ge ry, se ve re trau ma or bur ns 
can al so in du ce SIRS. When a pa tie nt wi th SIRS 
acqui res a bac te rial in fec tion, he may de ve lop sep-
sis, whi ch can fur ther prog re ss to se ve re sep sis, 
septic sho ck and fi  nal ly dea th (2,3). Des pi te ad van-
ces in an ti bio ti cs treat me nt, the mor ta li ty of sep sis 
is sti ll hi gh; so me stu dies re po rt up to 50% of pa-
tien ts dyi ng of sep sis (4,5). A ma jor rea son for this 
hi gh mor ta li ty is that treat me nt is of ten star ted at 
a ti me whe re irre ver sib le da ma ge is al rea dy in fl ic-
ted. On ce sep sis is cli ni cal ly sus pec ted, ear ly com-
men ce me nt of an ti bio tic the ra py in crea ses the 
chan ce of sur vi val (6).
The gol den stan da rd for diag no si ng sepsis is sti ll 
blood cul tu re (7,8). A se rious di sad van ta ge of this 
te st is that it can ta ke up to 2 days be fo re the fi  nal 
re su lt is avai lab le and du ri ng this pe riod, the con-
di tion of a sep tic pa tie nt can ra pid ly de te rio ra te. 
The re fo re, it is com mon prac ti ce to sta rt the ra py 
Hoff ma nn JJML.  Neut rop hil CD64 as a sep sis bio mar ker
Biochemia Medica 2011;21(3):282–90
  283
wi th broa d-spec trum an ti bio ti cs be fo re the resul ts 
of blood cul tu re are known. Howe ver, ad mi nis tra-
tion of an ti bio ti cs to pa tien ts who ha ve no bac te-
rial in fec tion is not on ly un ne ces sa ry, but is expen si-
ve and can con tri bu te to de ve lo pi ng bac te rial re sis-
tan ce to an ti bio ti cs, too. The re fo re, cli ni cia ns are in 
need of bio mar ke rs that can re liab ly de te ct sep sis 
or its as so cia ted in fec tion in an ear ly sta ge or exclu-
de in fec tion so that ti me ly de ci sio ns on star ti ng or 
ter mi na ti ng an tibiotic treat me nt can be ma de (7,8).
Neut rop hil CD64 as a bio mar ker
Expres sion of the CD64 an ti gen on neut rop hi ls has 
been un der in ves ti ga tion for so me yea rs as a bio-
mar ker of in fec tion and sep sis. It has se ve ral cha-
rac te ris ti cs that ma ke is we ll sui ted for cli ni cal ap-
pli ca tion: on res ti ng neut rop hi ls CD64 expres sion 
is low and af ter ac ti va tion it is sig ni fi  can tly up re gu-
la ted wit hin few hou rs. On ce the ac ti va tion sti mu lus 
di sap pea rs, CD64 expres sion re tur ns to its ba sal le-
vel in few days. Mo reo ver, CD64 is re la ti ve ly stab le 
af ter blood col lec tion and the as say is straig htfo-
rwa rd and requi res on ly sma ll sam ple vo lu me. La st 
but not lea st, CD64 expres sion rep re sen ts a physio-
lo gi cal pro ce ss whi ch plays a key ro le in the in na te 
im mu ne res pon se: neut rop hi ls ac ti ng as pha go cytes.
The CD64 an ti gen is the hi gh affi   ni ty re cep tor for 
the Fcγ pa rt of the IgG hea vy chain and can bi nd 
mo no me ric Ig G1 and Ig G3 as we ll as ag gre ga ted 
IgG (9). Pha go cyto sis of bac te ria and ot her mic roor-
ga nis ms is me dia ted by this FcγRI re cep tor. In con-
tra st to mo no cytes whe re CD64 an ti gen is con sti tu-
ti ve ly expres sed, res ti ng neut rop hi ls ha ve ve ry low 
le ve ls of CD64 an ti gen on their mem bra ne, ap proxi-
ma te ly 1000 mo le cu les per ce ll (10). CD64 expres-
sion is in crea sed upon ac ti va tion of neut rop hi ls by 
pro-in fl am ma to ry cyto ki nes wit hin 4-6 hou rs and 
can rea ch mo re than 10-fold hig her le ve ls than in 
res ti ng con di tio ns, al lowi ng good dis cri mi na tion 
be tween res ti ng and ac ti va ted neut rop hi ls (11,12).
Diag nos tic per for man ce in adul ts wi th 
sep sis
In the la st few yea rs va rious in ves ti ga to rs ha ve fo-
cu sed their re sear ch on the cli ni cal uti li ty of neut-
rop hil CD64 as a mar ker for sep sis or syste mic in-
fec tion (Tab le 1). Da vis was the fi r st who re por ted 
a stu dy in whi ch CD64 was mea su red in pa tien ts 
who we re la ter de ter mi ned to ha ve had sep sis (13). 
As this stu dy was ret ros pec ti ve and sam ples se lec-
tion was per for med in the he ma to lo gy la bo ra to ry, 
it shou ld be be st re gar ded as a “proof of prin cip le” 
in ves ti ga tion. Anyway, it de mon stra ted the diag-
nos tic po ten tial of CD64 and al so showed that 
neut rop hil CD64 per for med better than all ot her 
la bo ra to ry tes ts that we re then in use. A sub seque-
nt stu dy by the sa me group pros pec ti ve ly in clu-
ded pa tien ts pre sen ti ng at the emer gen cy de par-
tme nt. The re sul ts con fi r med tho se of their pre-
vious stu dy: CD64 had the hig he st sen si ti vi ty and 
spe ci fi  ci ty in de tec ti ng syste mic in fec tion or sep sis 
(14). Re mar kab ly, the cu t-o ff  le vel used for neut rop-
hil CD64 was con si de rab ly lower than in the fi r st 
stu dy; un for tu na te ly an expla na tion was not pro vi-
ded (13,14). Li va di ti and cowor ke rs re por ted the fi r st 
stu dy that en rol led cri ti cal ly ill pa tien ts from an in-
ten si ve ca re unit (ICU), whi ch rep re sen ts the cli ni cal 
si tua tion in whi ch sep sis bio mar ke rs li ke ly ha ve the 
mo st re le va nt ap pli ca tion. The se aut ho rs fou nd that 
se rum in ter leu ki n-6 (IL-6) and IL-8 as we ll as neut-
rop hil CD64 best eva lua ted the se ve ri ty of sep sis in 
an ear ly sta ge, whe reas CD64 and IL-8 cou ld al so 
pre di ct mor ta li ty (15). A lar ger stu dy in vol vi ng adu lt 
sep sis pa tien ts was pub lis hed by Car del li et al (16). 
They in clu ded 112 ICU pa tien ts who we re cli ni cal ly 
sus pec ted of ha vi ng sep sis; in 52 of the se pa tien ts 
sep sis was pro ven by po si ti ve blood cul tu re. Neut-
rop hil CD64 was ab le to dis tin gui sh the se pa tien ts 
from the ones in whom sep sis cou ld not be pro ven 
wi th ve ry hi gh sen si ti vi ty and spe ci fi  ci ty. Mo reo-
ver, CD64 ap pea red to be mo re spe ci fi c than pro-
cal ci to nin (16). A si mi lar stu dy, al beit in a mu ch 
lower num ber of pa tien ts, was un der ta ken by Da-
ni kas and col lea gues, who showed that hi gh CD64 
expres sion on neut rop hi ls was fa vo rab ly cor re la-
ted wi th sur vi val (17). Anot her sma ll stu dy in
patients sus pec ted of sep sis thus far on ly ap pea-
red as an ab stra ct wi th li mi ted de tai ls; al so he re high 
sen si ti vi ty and spe ci fi  ci ty for iden ti fyi ng patients 
wi th po si ti ve blood cul tu re was re por ted (18).
Fur t her, a re ce nt re po rt by Hsu et al showed that in 
pa tien ts in a res pi ra to ry ICU neut rop hil CD64 was 
bet ter than pro cal ci to nin for dis tin guishi ng SIRS 
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from se ve re sep sis and sep tic sho ck (19). In ad di-
tion, CD64 was fou nd to be as so cia ted wi th mor ta-
li ty in this stu dy. Ve ry re cen tly Gáme z-Díaz et al. 
pub lis hed the re sul ts of the lar ge st stu dy ever (20). 
They in ves ti ga ted emer gen cy de par tme nt pa tien-
ts wi th sus pec ted in fec tion, fe ver, de li rium or acu-
te hypo ten sion of un clear ori gin. Of the 631 pa tien-
ts in clu ded, 416 (66%) we re dee med to ha ve sep sis. 
The sen si ti vi ty of neut rop hil CD64 for a diag no sis of 
sep sis was 66% and the spe ci fi  ci ty 65% (20).
A cri ti cal over view of al mo st all the abo ve stu dies 
is pro vi ded in two re ce nt re view pa pe rs (21,22). 
Un for tu na te ly, mo st of the stu dies ha ve been per-
for med on re la ti ve ly sma ll pa tien ts grou ps and ha-
ve se rious met ho do lo gi cal shor tco min gs (22). No-
net he le ss, the re sul ts are ge ne ral ly we ll in ag ree-
me nt. The poo led sen si ti vi ty of CD64 for de tec ti ng 
in fec tion or sep sis was re por ted as 79% and the 
spe ci fi  ci ty 91% (22). Howe ver, the cal cu la tio ns in 
this me ta-a na lysis we re per for med usi ng stu dies 
wi th hig hly va riab le de si gn: bo th adul ts and neo-
na tes we re in clu ded and pa tien ts wi th sep sis, 
syste mic in fec tio ns and lo cal in fec tio ns we re 
mixed, whi ch is not rep re sen ta ti ve of neut rop hil 
CD64 as a sep sis bio mar ker. When con si de ri ng stu-
dies on sep tic adu lt pa tien ts on ly, the ove ra ll sen si-
ti vi ty wou ld be 88.3% (95% con fi  den ce in ter val 
78.1-94.1%) whi le the spe ci fi  ci ty wou ld amou nt to 
87.6% (71.8-95.2%) (Tab le 1). Com bi ni ng the se stu-
dies has its li mi ta tio ns, thou gh. The in di vi dual stu-
dies had hig hly diff e re nt de sig ns, the in clu sion cri-
te ria we re not always si mi lar, they ge ne ral ly used 
sma ll num be rs of pa tien ts and the re was sub stan-
tial va ria tion in ana lyti cal met ho do lo gy as we ll as 
in de fi  ni tion of the cu t-o ff  va lue (Tab le 1). Ta ken to-
get her, the re is evi den tly a need for mu ch lar ger, 
mul ti cen ter stu dies wi th uni fo rm in clu sion cri te ria 
and stan dar di zed ana lyti cal met ho ds in or der to 
ful ly ap pre cia te the cli ni cal uti li ty of neut rop hil 
CD64 as a sep sis mar ker in an ICU set ti ng.
Diag nos tic per for man ce in neo na tes and 
chil dren wi th sep sis
Neo na tal sep sis is diff e re nt from adu lt sep sis in se-
ve ral res pec ts and the re fo re a se pa ra te dis cus sion 
Stu dy 
(re fe ren ce) N Pa tie nt se lec tion cri te ria
Sen si ti vi ty / 
Spe ci fi  ci ty
AUC
(95% CI) Cu t-o ff  va lue
Da vis (13) 160
Ran dom se lec tion in the he ma to lo gy la bo ra to ry, 
ret ros pec ti ve clas si fi  ca tion as to in fl am ma tion, 
in fec tion or sep sis by cli ni cal sco re
94% / 85% - 5000 MESF uni ts
Da vis (14) 100
Ran dom se lec tion of pa tien ts in the emer gen cy 
de par tme nt, ret ros pec ti ve clas si fi  ca tion as to 
in fl am ma tion, in fec tion or sep sis by cli ni cal sco re
88% / 77% - 2000 MESF uni ts
Li va di ti (15) 47 Sep sis; se ve re sep sis; sep tic sho ck 95% / 100% 0.98(-) 2566 mo le cu les/cell
Car del li (16) 112 Sep sis wi th po si ti ve blood cul tu re; sep sis sus pec ted, but ne ga ti ve blood cul tu re 96% / 95%
0.97
(-) 2398 mo le cu les/cell
Da ni kas (17) 31 Se ve re sep sis or sep tic sho ck 60% / 100% 0.892(-) MFI 2.45
Lob reg lio (18) 30 Sep sis wi th po si ti ve blood cul tu re; con trol pa tien ts wit hout in fec tion 92% / 100% - CD64 in dex 1.5
Hsu (19) 66 Sep tic sho ck; se ve re sep sis; SIRS wi th acu te res pi ra to ry fai lu re 89% / 96%
0.928
(-) 4300 mo le cu les/cell
Gáme z-Díaz (20) 361
Emer gen cy de par tme nt pa tien ts wi th pos sib le 
sep sis (in fec tion, fe ver of un known cua se, 
de li rium or unexplai ned hypo ten sion)
66% / 65% 0.706(0.664-0.748) CD64 in dex 1.7
AUC - area un der the ROC cur ve; CI - con fi  den ce in ter val; MESF - mo le cu les of equi va le nt so lub le fl uo roc hro mes; MFI - mean 
fl uo res cen ce in ten si ty.
TAB LE 1. Sum ma ry of stu dies on the diag nos tic per for man ce of neut rop hil CD64 in adu lt pa tien ts wi th sep sis.
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is war ran ted. The cli ni cal sig ns and sympto ms of-
ten are mo re sub tle and no n-spe ci fi c than in 
adults, a cli ni cal sco re system has no clear ad van-
ta ge and tra di tio nal la bo ra to ry tes ts ha ve poor 
diag nos tic per for man ce (23,24). The re fo re, neut-
rop hil CD64 wou ld be a can di da te sep sis bio mar-
ker al so in neo na tes and chil dren. Howe ver, heal-
thy neo na tes re por ted ly ha ve hig her CD64 expres-
sion on their neut rop hi ls than adul ts (25,26), whi ch 
mig ht in fl uen ce the diag nos tic power of the te st.
Tab le 2 sum ma ri zes the cur re nt li te ra tu re on neut-
rop hil CD64 as a bio mar ker for neo na tal and chil d-
hood sep sis. Layse ca-Es pi no sa et al. showed that 
neut rop hil CD64 was a hig hly spe ci fi c in di ca tor of 
neo na tal sep sis, al beit wi th low sen si ti vi ty (27). 
The se aut ho rs used the per cen ta ge of CD64-po si-
ti ve cel ls as a cri te rion; howe ver, it has been shown 
that CD64 fl uo res cen ce in ten si ty, eit her as mean 
fl uo res cen ce in dex (MFI) or as an in dex re la ti ve to 
stan da rd bea ds, is a bet ter dis cri mi na tor than per-
cen ta ge CD64-po si ti ve neut rop hi ls (28,29). Ng and 
col lea gues de mon stra ted the uti li ty of CD64 as a 
bio mar ker of la te-on set in fec tion in pre te rm, ve ry 
low bir thweig ht in fan ts: bo th at the fi r st cli ni cal 
sus pi cion of sep sis as we ll as 24 hou rs la ter, the 
diag nos tic per for man ce of neut rop hil CD64 was 
mu ch bet ter than all ot her mar ke rs in ves ti ga ted 
(30). The com bi na tion of neut rop hil CD64 expres-
Stu dy (re fe ren ce) N Pa tie nt se lec tion cri te ria Sen si ti vi ty / Spe ci fi  ci ty
AUC
(95% CI) Cu t-o ff  va lue
Layse ca-Es pi no sa 
(27) 63
Neo na tes wi th cul tu re-po si ti ve sep sis; 
neo na tes wi th cul tu re-ne ga ti ve, cli ni cal sep sis; 
se ve re ly ill neo na tes wit hout in fec tion; heal thy 
newbor ns
26% / 97% - 31% CD64+ cel ls
Ng (30) 110
Pre te rm in fan ts wi th cul tu re-pro ven in fec tion; 
pre te rm in fan ts wi th sus pi cion of sep sis, but no 
in fec tion pro ven; heal thy, ve ry low bir th weig ht 
pre te rm in fan ts
95% / 88% - 4000 mo le cu les/cell
Ng (31) 359
Te rm in fan ts wi th cul tu re-pro ven in fec tion; 
te rm in fan ts wi th sus pi cion of sep sis, but no 
in fec tion pro ven; heal thy, te rm in fan ts
97% / 72% 0.88 (0 h)0.94 (24 h) 5500 mo le cu les/cell
Gro se lj-Gre nc (29) 56
Neo na tes and chil dren wi th SIRS and 
cul tu re-pro ven sep sis; neo na tes and chil dren 
wi th SIRS
86% / 100% - CD64 in dex 2.19
Bhan da ri (33) 173
Neo na tes wi th cul tu re-pro ven sep sis; neo na tes 
wi th sus pec ted sep sis, but in fec tion pro ven; 
neo na tes wit hout sep sis
80% / 79% 0.852(0.806-0.890) CD64 in dex 4.02
Gro se lj-Gre nc (32) 36 Neo na tes wi th SIRS and cul tu re-pro ven sep sis; neo na tes wi th SIRS 77% / 79%
0.82
(0.68-0.92) CD64 in dex 1.86
Gro se lj-Gre nc (32) 36 Chil dren wi th SIRS and cul tu re-pro ven sep sis; chil dren wi th SIRS 71% / 100%
0.88
(0.73-0.97) CD64 in dex 2.38
Dil li (34) 109
Neo na tes wi th pro ven sep sis; neo na tes wi th 
cli ni cal sep sis; neo na tes wi th no n-in fec tious 
di sea se; heal thy newbor ns
87% / 85% 0.90(0.83-0.96)
MFI 87.7
CD64 in dex 4.39
Zei toun (35) 98
Neo na tes wi th cul tu re-pro ven sep sis; neo na tes 
wi th cli ni cal sep sis, cul tu re ne ga ti ve; heal thy 
newbor ns
92% / 71% 0.94(0.86-0.99) CD64 in dex 2.6
Lam (36) 310
Neo na tes wi th in tra-ab do mi nal sep sis; 
neo na tes wi th extra-ab do mi nal sep sis; 




(-) 6010 mo le cu les/cell
AUC - area un der the ROC cur ve; CI - con fi  den ce in ter val; MFI - mean fl uo res cen ce in ten si ty.
TAB LE 2. Sum ma ry of stu dies on the diag nos tic per for man ce of neut rop hil CD64 in neo na tes, in fan ts and chil dren wi th sep sis.
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sion wi th eit her se rum C-reac ti ve pro tein or IL-6 
even en han ced the sen si ti vi ty to 100%, mea ni ng 
that the se mar ke rs to get her can be used to exclu-
de in fec tion (30). So me yea rs la ter the sa me group 
pub lis hed a ve ry si mi lar stu dy, but now on ear ly-
on set in fec tion in te rm in fan ts; they en rol led the 
lar ge st num ber of pa tien ts re por ted up to now. 
This stu dy con fi r med the ve ry hi gh sen si ti vi ty of 
neut rop hil CD64, but in con tra st to their pre vious 
stu dy ad di tion of CRP im pro ved the diag nos tic 
power of CD64 on ly mar gi nal ly (31). A smal ler stu-
dy in cri ti cal ly ill neo na tes and in fan ts by Gro se lj-
Gre nc used the stan dar di zed CD64 in dex for the 
fi r st ti me and de mon stra ted its su pe rio ri ty over all 
ot her in fec tion mar ke rs (29). In a fol low-up stu dy 
the sa me aut ho rs pre sen ted evi den ce that neut-
rop hil CD64 was the be st in di vi dual mar ker for 
bac te rial sep sis in chil dren, whe reas the te st per-
for med so mewhat le ss in neo na tes (32). Howe ver, 
bo th pa tie nt grou ps we re of li mi ted si ze and might 
ac tual ly not war ra nt this con clu sion. Bhan da ri et al. 
con duc ted the thi r d-lar ge st stu dy in neo na tes with 
sus pec ted sep sis and al so the se aut ho rs fou nd 
that neut rop hil CD64 in dex had the be st diag no-
stic per for man ce for cul tu re-po si ti ve sep sis com-
pa red wi th all tra di tio nal he ma to lo gic as says (33). 
In the stu dy by Dil li et al., per for med on over 100 
pa tien ts in a neo na tal ICU, the neut rop hil CD64 in-
dex again was fou nd to be the te st wi th the hig he-
st sen si ti vi ty, wi th no diff e ren ce be tween neut rop-
hil CD64 in dex and MFI (34). Com bi na tion of CD64 
in dex wi th CRP and IL-6 in crea sed the sen si ti vi ty 
and the ne ga ti ve pre dic ti ve va lue to 100%, al lowi-
ng re liab le exclu sion of in fec tion. Slig htly lower 
diag nos tic per for man ce was re por ted by Zei toun 
and cowor ke rs, al so when the CD64 in dex was 
com bi ned wi th se rum IL-10 (35). Re cen tly, Lam et 
al. de mon stra ted in a lar ge-sca le stu dy that neut-
rop hil CD64 was use ful in neo na tes sus pec ted of 
ab do mi nal in fec tion and sep sis, in par ti cu lar in 
com bi na tion wi th con ven tio nal X-ray ima gi ng for 
exclu di ng an in fec tious cau se of di sea se (36).
Ove ra ll, the se ni ne stu dies in neo na tes and chil-
dren gi ve a rea so nab ly con sis te nt im pres sion of 
the diag nos tic per for man ce of neut rop hil CD64 in 
sep sis and se ve re in fec tion. The com po si te sen si ti-
vi ty (83.4%; 95% CI = 70.0-91.5%) and spe ci fi  ci ty 
(86.2%; 95% CI = 75.2-92.7%) show that CD64 rep-
re sen ts one of the mo st sen si ti ve bio mar ke rs of 
pe diat ric sep sis cur ren tly avai lab le for cli ni cal use.
Un til re cen tly it see med that neut rop hil CD64 had 
hig her sen si ti vi ty and spe ci fi  ci ty in adul ts wi th sep-
sis than in neo na tes and chil dren. Howe ver, the 
mo st re ce nt pa per (20) chan ged the si tua tion. The 
sum ma ry ROC cur ves of adul ts and neo na tes and 
chil dren do no lon ger show sta tis ti cal diff e ren ces 
and the re fo re can re liab ly be com bi ned. The ove-
ra ll sum ma ry ROC cur ve de mon stra tes that neut-
rop hil CD64 can de te ct sep sis wi th a sen si ti vi ty of 
85.7% (95% CI = 77.5-91.2%) and spe ci fi  ci ty of 
87.4% (95% CI = 79.3-92.6%), as shown in Fi gu re 1. 
The po si ti ve li ke li hood ra tio is 6.79 (95% CI = 4.02-
11.47) and the ne ga ti ve li ke li hood ra tio 0.16 (95% 
CI = 0.10-0.26).
FI GU RE 1. Sum ma ry ROC cur ve of 17 stu dies re por ti ng on the 
diag nos tic per for man ce of neut rop hil CD64 as a sep sis bio mar-
ker. Ea ch stu dy is rep re sen ted by a squa re, the si ze of whi ch is 
pro por tio nal to the num ber of pa tien ts in clu ded. The bla ck dot 
is the com po si te sen si ti vi ty and spe ci fi  ci ty; the area arou nd it 
rep re sen ts the 95% con fi  den ce ran ge.
Mar ker of di sea se se ve ri ty
Neut rop hil CD64 expres sion is not on ly use ful for 
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se ve ral aut ho rs ha ve al so re por ted its va lue as an 
in di ca tor of sep sis se ve ri ty: pa tien ts wi th sep tic 
sho ck ge ne ral ly show the hig he st CD64 va lues, 
hig her than in se ve re sep sis and mu ch hig her than 
in sep sis and SIRS (12,15,19,37). The lat ter aut ho rs 
al so de mon stra ted that pa tien ts re cei vi ng adequa-
te an ti bio tic the ra py had a qui ck dec rea se of their 
CD64 in dex, in pa ral lel wi th an im pro ve me nt in 
their cli ni cal con di tion (37). It is not on ly in sep sis 
that CD64 is a good in di ca tor of di sea se se ve ri ty; 
the sa me fi n di ng has been re por ted in lo cal in fec-
tio ns, too (38).
Prog nos tic in for ma tion
Accor di ng to se ve ral aut ho rs, neut rop hil CD64 
con tai ns al so prog nos tic in for ma tion as to sur vi val. 
Howe ver, the avai lab le da ta are hig hly con tra dic-
to ry. Se ve ral pub li ca tio ns re por ted that sur vi val 
cou ld be pre dic ted by a low CD64 expres sion 
(12,15,19,39,40), whe reas ot he rs in di ca ted that hi gh 
CD64 wou ld be an in di ca tor of fa vo rab le prog no-
sis (17,41). Mo st li ke ly the sma ll pa tie nt grou ps and 
the de si gn of the stu dies explain the se con fl ic ti ng 
fi n din gs.
Diag nos tic per for man ce in ot her 
in fec ti ve and in fl am ma to ry di sea ses
Apa rt from syste mic in fec tion and sep sis, the re is a 
wi de va rie ty of ot her di sea se sta tes in whi ch the 
diag nos tic uti li ty of neut rop hil CD64 has been sug-
ges ted. One of the mo st use ful ap pli ca tio ns is pro-
bab ly the abi li ty of neut rop hil CD64 to dis tin gui sh 
be tween bac te rial in fec tion and acu te fl a res in 
rheu ma toid ar thri tis and ot her au toim mu ne di sor-
de rs (42-47). Fur ther, CD64 has been fou nd use ful 
as a mar ker of pos to pe ra ti ve in fec tion in pa tien ts 
un der goi ng mus cu los ke le tal (38), car diac (48) or 
vas cu lar sur ge ry (49). CD64 in dex was a va luab le 
tool in in fl am ma to ry bowel di sea se, too (50). A re-
ce nt re view in di ca ted that neut rop hil CD64 is not 
on ly in crea sed in bac te rial in fec tion, but al so in vi-
ral in fec tion, de pen di ng on the type of vi rus (26). 
Fi nal ly, CD64 has suc ces sful ly been used in fa mi lial 
Me di ter ra nean fe ver (51) and as a re jec tion mar ker 
in tran spla nt pa tien ts (52).
Ana lyti cal as pec ts of neut rop hil CD64 
as say
Flow cyto met ry is the met hod of choi ce for de ter-
mi ni ng neut rop hil CD64. In the ear ly yea rs aut ho rs 
used den si ty gra die nt cen tri fu ga tion for iso la ti ng 
neut rop hi ls fol lowed by in di re ct im mu nofl uo res-
cen ce for de tec ti ng CD64 expres sion. Nowa days, 
vir tual ly all in ves ti ga to rs use di re ct im mu nofl uo-
res cen ce in who le blood usi ng a lyse-no-wa sh 
met hod (13,29). The in tra-la bo ra to ry im pre ci sion 
see ms to be low wi th coeffi   cie nt of va ria tion 3-6% 
and < 12%, res pec ti ve ly (53,54). Da ta on the in te r-
la bo ra to ry va ria tion ha ve not been re por ted. The 
as say can con ve nien tly be per for med in a sma ll 
vo lu me of ED TA-an ti coa gu la ted blood and the 
CD64 an ti gen is stab le for 36 or 72 hou rs at room 
tem pe ra tu re (13,50).
Li ke wi th mo st fl ow cyto met ric as says, the de ter-
mi na tion of neut rop hil CD64 lac ks stan dar di za-
tion. As shown in Tab les 1 and 2, va rious met ho ds 
are in use for expres si ng CD64 on neut rop hi ls: per-
cen ta ge of CD64-po si ti ve cel ls, mean or me dian 
fl uo res cen ce in ten si ty (MFI) and as an in dex re la ti-
ve to stan dar di zed bea ds. The lat ter met hod is 
avai lab le as a com mer cial kit (Tril lium Diag nos ti cs, 
Brewer, ME, USA). It co mes in two for ma ts: one for 
use on fl ow cyto me te rs (32,35,37,55) and one for 
the CELL-DYN Sap phi re he ma to lo gy ana lyzer,
which al lows prac ti cal fu ll au to ma tion and does 
not requi re fl ow cyto met ry exper ti se (18,41,54,56). 
Bo th kit met ho ds use FI TC-la be led CD64 and PE-
la be led CD163 mo noc lo nal an ti bo dies and con tain 
ca lib ra ted fl uo res ce nt bea ds for stan dar di za tion. 
Lympho cytes and mo no cytes are used as ne ga ti ve 
and po si ti ve in ter nal con trol, res pec ti ve ly. The as-
say requi res 50 µL of blood and can be com ple ted 
wit hin 1 hour on a stan da rd fl ow cyto me ter and 
wit hin 20 mi nu tes on the Sap phi re ana lyzer. 
Thanks to the ca lib ra ted bea ds, the kit met hod has 
the po ten tial of in te r-la bo ra to ry com pa ra bi li ty of
re sul ts, al thou gh da ta ha ve not yet been pub lis hed.
Cri ti cal as ses sme nt of the li te ra tu re
The ge ne ral pic tu re that ari ses when rea di ng the 
avai lab le li te ra tu re is that neut rop hil CD64 see ms 
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to be a hig hly sen si ti ve and rea so nab ly spe ci fi c 
bio mar ker for sep sis and ot her in fec tio ns. Howe-
ver, the re are se ve ral fac to rs that shou ld nuan ce 
the se po si ti ve re por ts. The two mo st im por ta nt 
ha ve al rea dy been men tio ned abo ve: near ly all 
stu dies in clu ded re la ti ve ly sma ll pa tie nt num be rs 
and the met ho do lo gi cal qua li ty of re por ted stu-
dies is me dioc re (22). In ad di tion, the re is an enor-
mous va ria tion in cri te ria for se lec ti ng pa tien ts, 
diff e ren ces in the de fi  ni tion of sep sis as we ll as 
poor ly stan dar di zed ana lyti cal met ho do lo gy. Some-
ti mes, heal thy sub jec ts are used as a con trol gro-
up, whi ch does not rep re se nt the con di tio ns in 
whi ch a sep sis bio mar ker is cli ni cal ly used and more-
o ver, this prac ti ce can ea si ly ove res ti ma te the 
power of a diag nos tic te st.
This all does not mean that we shou ld dis re ga rd 
the se stu dies. They pre se nt a hig hly pro mi si ng and 
stro ng in di ca tion, but not suffi   cien tly so lid scien ti-
fi c evi den ce that neut rop hil CD64 expres sion is a 
bio mar ker for sep sis that can be re com men ded for 
rou ti ne use. This nee ds to be con fi r med by lar ge-
sca le, pros pec ti ve, mul ti cen ter, pre fe rab ly ca se-
con trol stu dies of good met ho do lo gi cal qua li ty. 
The de fi  ni tion of sep sis shou ld be in ac cor dan ce 
with wi de ly ac cep ted cri te ria (2,3), blood cul tu res 
shou ld be per for med as the re fe ren ce stan da rd, 
pa tien ts in whom sep sis was cli ni cal ly sus pec ted 
but cou ld not be ob jec ti ve ly pro ven shou ld be 
used rat her than heal thy con tro ls for cal cu la ti ng 
sen si ti vi ty and spe ci fi  ci ty for sep sis pa tien ts, the 
ana lyti cal met hod for CD64 shou ld be stan dar di-
zed and ca lib ra ted usi ng bea ds. In ad di tion, di sea-
se se ve ri ty shou ld be sco red usi ng we ll ac cep ted 
syste ms and the cli ni cal fol low-up shou ld be lo ng 
enou gh to do cu me nt sep si s-re la ted mor ta li ty. Fur-
ther mo re it wou ld be in te res ti ng to stu dy neut ro-
p hil CD64 as a tool for mo ni to ri ng the ra py, li ke is 
cur ren tly bei ng do ne for pro cal ci to nin.
Con clu sio ns
Des pi te the poor met ho do lo gi cal qua li ty of the 
avai lab le li te ra tu re, it is evi de nt that neut rop hil 
CD64 is a ve ry pro mi si ng sep sis bio mar ker, un-
doub ted ly mu ch bet ter than tra di tio nal he ma to lo-
gic pa ra me te rs and CRP and pro bab ly al so bet ter 
than pro cal ci to nin (57). Neut rop hil CD64 see ms to 
per fo rm equal ly we ll in adul ts and in neo na tes and 
in fan ts. The CD64 as say is re la ti ve ly sim ple and can 
ea si ly be im ple men ted in prac ti ce. Howe ver, va li-
da tion in lar ge mul ti cen ter stu dies is requi red be-
fo re neut rop hil CD64 can be re com men ded as a 
sep sis bio mar ker for rou ti ne use in ICU pa tien ts.
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Neut ro fi l ni an ti gen CD64 kao bio loš ki bi ljeg sep se
Sažetak
Neut ro fi l ni gra nu lo ci ti iz ra ža va ju svoj re cep tor za Fcy frag me nt, poz nat kao neut ro fi l ni an ti gen CD64, ug lav nom ka da su ak ti vi ra ni. To či ni neut ro-
fi l ni an ti gen CD64 po ten ci jal nim bio loš kim bi lje gom za in fek ci je i sep su. Pos to ji op sež na li te ra tu ra o di jag nos tič koj prim je ni neut ro fi l nog an ti ge-
na CD64 kod raz nih bo les ti. Ovaj se preg led us re do to ču je na nje go vu prim je nu kao bio loš kog bi lje ga sep se kod od ras lih kao i kod no vo ro đen ča di 
i dje ce. Dos tup ni po da ci uka zu ju da neut ro fi l ni an ti gen CD64 ima vi so ku os jet lji vo st (86%) i spe ci fi č no st (87%), no me to do loš ka kva li te ta ve ći ne 
tih is pi ti va nja je upit na. Me đu tim, iz gle da da neut ro fi l ni an ti gen CD64 pred stav lja bo lji di jag nos tič ki te st ne go što su to tra di cio nal ne he ma to-
loš ke pret ra ge, C-reak tiv ni pro tein, pa čak i pro kal ci to nin. Prim je na neut ro fi l nog an ti ge na CD64 u os ta lim uv je ti ma osim kod sep se vr lo je štu ro 
pri ka za na. Na kra ju tre ba na po me nu ti da su pot reb na dalj nja kli nič ka is tra ži va nja ka ko bi se pot vr dio di jag nos tič ki uči nak ovog obe ća va ju ćeg 
bio loš kog bi lje ga.
Ključ ne ri je či: bio loš ki bi ljeg; neut ro fi l ni an ti gen CD64; in fek ci ja; neut ro fi l ni gra nu lo cit; sep sa
